Clinical Trial Detail

NCT ID NCT03084471
Title An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors AstraZeneca
Indications

urinary system cancer

Therapies

Durvalumab + Tremelimumab

Durvalumab

Age Groups: senior adult

No variant requirements are available.